A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
== History == The company was listed on the Australian Stock Exchange in 1987 as Sonic Technology Australia Ltd. Which took the pathology practice of Douglass Laboratories. In 1991, Douglass Laboratories opened a pathology branch in Adelaide, South Australia. In 1993, Colin Goldschmidt was appointed Managing Director for the group of laboratories. In 1997, Barratt Smith Moran Pathology changed its name to Capital Pathology. Sonic Healthcare acquired Lifescreen Australia. In 2000, Sonic Healthcare established its Core Values and introduced new management structures. In 2004, The Doctors Laboratory formed a partnership with the National Health Service's University College of London Hospital. In 2009, the company established the German Sonic Executive Committee to coordinate its German operations. In the US, Sonic Healthcare acquired Axiom Laboratories (Tampa, Florida) merging it with The Cognoscienti Health Institute, Piedmont Medical Laboratory (Winchester, Virginia), and East Side Clinical Laboratory (Rhode Island).
Termination of the growing polypeptide chain occurs when the ribosome encounters a stop codon (UAA, UAG, or UGA) in the mRNA molecule. When this occurs, no tRNA can recognise it and a release factor induces the release of the complete polypeptide chain from the ribosome.
Tyrannosaurus lived during what is referred to as the Lancian faunal stage (Maastrichtian age) at the end of the Late Cretaceous. Tyrannosaurus ranged from Canada in the north to at least New Mexico in the south of Laramidia. Several notable Tyrannosaurus remains have been found in the Hell Creek Formation. During the Maastrichtian this area was maritime to subtropical, with a warm and humid climate. The flora consisted mostly of angiosperms, but also included trees like dawn redwood (Metasequoia). Archosaurs discovered from this formation include the ceratopsians Leptoceratops, Torosaurus, and Triceratops, the hadrosaurid Edmontosaurus annectens, the parksosaurid Thescelosaurus, the ankylosaurs Ankylosaurus and Denversaurus, the pachycephalosaurs Pachycephalosaurus, Platytholus and Sphaerotholus, the paravian theropods Acheroraptor and Pectinodon, other maniraptoran theropods Anzu, Eoneophron, Trierarchuncus and indeterminate ornithomimids, the tyrannosauroid Nanotyrannus, and the azhdarchid pterosaur Infernodrakon.
=== 1993 to 2011 list of genera === Following Taylor et al., from 1993 to 2011, the family Conidae was defined as including not only the cone snails, but also a large number of other genera which are commonly known as "turrids". However, as a result of molecular phylogeny studies in 2011, many of those genera were moved back to the Turridae, or were placed in new "turrid" families within the superfamily Conoidea. The following list of genera that used to be included in Conidae is retained as a historical reference:
Sources: en.wikipedia.org
TikTok enables content monetization to creators who meet specific requirements and reside in eligible areas. TikTok first offered this monetization in 2020 through the Creator Fund, which contained a finite amount of money split amongst creators that qualified for it. In 2024, this fund was replaced with the Creator Rewards Program. Creators that have a video reach the top 4% of the platform and have more than 100,000 followers are eligible to receive 50% of its ad revenue. TikTok also has a tool called Creative Exchange that connects creators with potential sponsorship deals. As the platform has grown significantly over time, companies have increasingly advertised through influencer marketing. The platform's algorithm also contributes to the influencer marketing potential, as it picks out content according to the user's preference. Sponsored content is not as prevalent on the platform as it is on other social media apps, but brands and influencers still can make as much as they would if not more in comparison to other platforms. Influencers on the platform who earn money through engagement, such as likes and comments, are referred to as "meme machines". In 2021, The New York Times reported that viral TikTok videos by young people relating the emotional impact of books on them, tagged with the label "BookTok", significantly drove sales of literature. Publishers were increasingly using the platform as a venue for influencer marketing. TikTok has also increased sales of adult coloring books.
=== Category:EC 1.21 (act on X-H and Y-H to form an X-Y bond) === Category:EC 1.21.1 Iodotyrosine deiodinase EC 1.21.1.1 Category:EC 1.21.3 Isopenicillin N synthase EC 1.21.3.1 Tetrahydrocannabinolic acid synthase EC 1.21.3.7 Category:EC 1.21.4 Category:EC 1.21.99 Thyroxine 5-deiodinase EC 1.21.99.3 Iodothyronine deiodinase EC 1.21.99.3 and EC 1.21.99.4
Yonath was a member of the United States National Academy of Sciences; the American Academy of Arts and Sciences; the Israel Academy of Sciences and Humanities; the European Academy of Sciences and Art and the European Molecular Biology Organization. On 18 October 2014, Yonath was named an ordinary member of the Pontifical Academy of Sciences by Pope Francis. Her awards and honors included the following:
The compound needs to be carried to its effector site, most often via the bloodstream. From there, the compound may distribute into muscle and organs, usually to differing extents. After entry into the systemic circulation, either by intravascular injection or by absorption from any of the various extracellular sites, the drug is subjected to numerous distribution processes that tend to lower its plasma concentration. Distribution is defined as the reversible transfer of a drug between one compartment to another. Some factors affecting drug distribution include regional blood flow rates, molecular size, polarity and binding to serum proteins, forming a complex. Distribution can be a serious problem at some natural barriers like the blood–brain barrier.
One month later, the Phillips group independently reported the wild-type GFP structure in Nature Biotechnology. These crystal structures provided vital background on chromophore formation and neighboring residue interactions. Researchers have modified these residues by directed and random mutagenesis to produce the wide variety of GFP derivatives in use since then. Further research into GFP has shown that it is resistant to detergents, proteases, guanidinium chloride (GdmCl) treatments, and drastic temperature changes.
Sources: en.wikipedia.org
With mutual arrangement with Leuven, he became professor in both universities from 1962, dividing his time between Leuven and New York. In 1974, the same year he received his Nobel Prize, he founded the ICP, which would later be renamed the de Duve Institute. He became emeritus professor of the University of Louvain in 1985, and of Rockefeller in 1988. De Duve was granted the rank of Viscount in 1989 by King Baudouin of Belgium. He was also a recipient of Francqui Prize, Gairdner Foundation International Award, Heineken Prize, and E.B. Wilson Medal. In 1974, he founded the International Institute of Cellular and Molecular Pathology in Brussels, eventually renamed the de Duve Institute in 2005. He was the founding President of the L'Oréal-UNESCO For Women in Science Awards. He died by legal euthanasia after long suffering from cancer and atrial fibrillation.
Eastern Theater Command Southern Theater Command Western Theater Command Northern Theater Command Central Theater Command The service headquarters retain operational control in some areas within China and outside of China. For example, army headquarters controls or is responsible for the Beijing Garrison, the Tibet Military District, the Xinjiang Military District, and border and coastal defences. The counterpiracy patrols in the Gulf of Aden are controlled by navy headquarters. The JSD nominally controls operations beyond China's periphery, but in practice this seems to apply only to army operations. Services and theater commands have the same grade. The overlap of areas or units of responsibility may create disputes requiring CMC arbitration. As part of the 2015 reforms, military regions were replaced by theatre commands in 2016. Military regions were − uinlike the theatre commands − army-centric peacetime administrative organizations, and joint wartime commands were created on-demand by the army-dominated General Staff Department.
== Feeding == The mouth of the Hydra is surrounded by tentacles. When feeding, Hydra extend their body to maximum length and then slowly extend their tentacles. The tentacles of Hydra are extensible and can be four to five times the length of the body. To search for prey, Hydra extends its tentacles and slowly maneuvers them, waiting for contact. Upon contact with a prey, the stenoteles discharges neurotoxins; the desmonemes on the tentacle (nematocysts) also discharge threads that coil around the prey. Most of the tentacles join in the attack within 30 seconds. Within two minutes, the tentacles move the prey into the open mouth aperture. Within ten minutes, the prey is engulfed and digestion commences. A Hydra, with a column length of approximately 3–30 mm when extended and a width of about 1 mm, can stretch its body wall to digest prey more than twice its size. After 2–3 days, the indigestible remains will be discharged through the mouth aperture via contractions.The Hydra's mouth is not permanent: When the Hydra closes its mouth, the cells surrounding the open mouth fuse together. These joints are then broken when the Hydra feeds again.
== Computational neuroscience == Metastability in the brain is a phenomenon studied in computational neuroscience to elucidate how the human brain recognizes patterns. Here, the term metastability is used rather loosely. There is no lower-energy state, but there are semi-transient signals in the brain that persist for a while and are different than the usual equilibrium state.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.